Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide

Retina

Volumn 33, Issue 3, 2013, Pages 522-531

  Zacharias, Leandro C ^a,b   Lin, Ton ^c   Migon, Rafael ^a   Ghosn, Corine ^c   Orilla, Werhner ^c   Feldmann, Barbara ^c   Ruiz, Guadalupe ^c   Li, Yong ^c   Burke, James ^c   Kuppermann, Baruch D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c ALLERGAN INC   (United States)

Author keywords

dissolution rate; durability; fluorescein angiography; intravitreous injection; particle size; pharmacodynamics; pharmacokinetics; rabbit; retina; triamcinolone acetonide

Indexed keywords

LEITER; RECOMBINANT VASCULOTROPIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EXPERIMENTAL RABBIT; FLUORESCENCE ANGIOGRAPHY; LIQUEFACTION; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; RETINOPATHY; VITREOUS BODY;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HALF-LIFE; INTRAVITREAL INJECTIONS; PARTICLE SIZE; PRESERVATIVES, PHARMACEUTICAL; RABBITS; RECOMBINANT PROTEINS; RETINAL NEOVASCULARIZATION; SOLUBILITY; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 84874948505     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182647f69     Document Type: Article

References (46)

1. Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006; 124:643-650
2. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-224
3. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenoǹs capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005;112:1557-1563
4. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112: 1916-1921
5. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003; 29:27-33
6. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22
7. Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol 2005;139:860-866
8. Burk SE, da Mata AP, Snyder ME, et al. Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg 2003;29: 645-651
9. Yamakiri K, Ushino E, Kimura K, Sakamoto T. Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am J Ophthalmol 2004;138:650-652
10. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloids during pars plana vitrectomy. Retina 2000; 20:554-555
11. Sonoda KH, Sakamoto T, Enaida H, et al. Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide. Ophthalmology 2004; 111:226-230
12. Yamamoto N, Ozaki N, Murakami K. Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole. Ophthalmologica 2004;32:56-59
13. Shah GK, Rosenblatt BJ, Smith M. Internal limiting membrane peeling using triamcinolone acetonide: Histopathologic confirmation. Am J Ophthalmol 2003;138:656-657
14. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61
15. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27: 431-432
16. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-390
17. Jonas JB, Kreissig I, Degenring RF. Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-1669
18. Gilles MC, Simpson JM, Billson FA, et al. Safety of intravitreal injection of triamcinolone: Results from a clinical trial. Arch Ophthalmol 2004;122:336-340
19. Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2004;242:184-188
20. Jonas JB, Kreissig I, Spandau, et al. Infectious and non-infectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141: 579-580
21. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone injection. Retina 2003;23:686-691
22. Wang LC, Yang CM. Sterile endophthalmitis following intravitreal injection of triamcinolone acetonide. Ocul Immunol Inflamm 2005;13:295-300
23. Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006. Retina 2009;29:207-213
24. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol 2007;91:1122-1124
25. Schweitzer KD, Eneh A, Gale J. Practice patterns of Canadian vitreoretinal specialists in diabetic macular edema treatment. Can J Ophthalmol 2011;46:227-231
26. Higashiyama T, Sawada O, Kakinoki M, et al. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol 2012. Epub ahead of print
27. Chang YS, Wu CL, Tseng SH, et al. In vitro benzyl alcohol citotoxicity: Implications for intravitreal use of triamcinolone acetonide. Exp Eye Res 2008;86:942-950
28. TRIESENCE-. Prescribing Information. Available at: Http://ecatalog. alcon.com/pi/Triesence-us-en.pdf. Accessed July 14, 2012
29. Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29:38-45
30. TRIVARIS™. Prescribing Information. Available at: Http://www. allergan.com/assets/pdf/trivaris-pi.pdf. Accessed December 20, 2011
31. The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard of care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion. Arch Ophthalmol 2009;127:1115-1129
32. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1459
33. Missel PJ, Horner M, Muralikrishnan R. Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model. Pharm Res 2010;27:1530-1546
34. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-1569
35. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110;2003:681-686
36. Kim H, Csaky KG, Gravlin L, et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina 2006;26:523-530
37. Eckardt H, Ding M, Lind M, et al. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg 2005;87: 1434-1438
38. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF- induced vascular leakage in a rabbit model of blood-retinal and blood-Aqueous barrier breakdown. Exp Eye Res 2005;80: 249-258
39. Balazs EA, Denlinger JL. Aging changes in the vitreous. In Sekuler R, Kline D, Dismukes K, eds. Aging and human visual function. Vol 2: Modern Aging Research. New York: Alan R Lis Colors Inc; 1982:45-57
40. O'Malley P. The pattern of vitreous syneresis: A study of 800 autopsy eyes. In: Irvine AR, O'Malley C, eds. Advances in Vitreous Surgery. Springfield, IL: Charles C Thomas Publisher; 1976
41. Dayhaw-Parker P. Retinal pigment epithelium melanin and ocular toxicity. Int J Toxicol 2002;21:451-454
42. Hughes PM, Krishnamoorthy R, Mitra AK. Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: A novel ocular microdialysis technique. J Ocul Pharmacol Ther 1996;12:209-224
43. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug toxicity. Invest Ophthalmol Vis Sci 2008;49:333-341
44. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417
45. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci 2010;51: 2135-2138
46. Moshfeghi AA, Nugent A, Nomoto H, et al. Triamcinolone acetonide preparations. Impact of crystal size on in vitro behavior. Retina 2009;29:689-698